Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

New classification of chronic GVHD: added clarity from the consensus diagnoses

Bone Marrow Transplantation volume 43, pages 149–153 (2009)Cite this article

Abstract

The Diagnosis and Staging Working Group of the NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD (CGVHD) recently proposed criteria for diagnosis and assessment of overall CGVHD severity. We retrospectively reviewed 54 consecutive patients diagnosed with CGVHD between January 2002 and December 2005 after sibling donor transplant to assess the applicability of the new criteria in prognosticating survival and transplant-related mortality (TRM). A total of 8 patients (15%) were reclassified as late onset/persistent or recurrent acute GVHD (late aGVHD), 15 (28%) had overlap syndrome and 31 (57%) had classic CGVHD. Three-year overall survival was worse in patients with late aGVHD (3-year probability 25% (95% CI 4–56%)) followed by overlap syndrome (3-year probability 87% (95% CI 56–96%)) and CGVHD (3-year probability 75% (95% CI 54–87%)); P=0.001. Among patients with overlap syndrome and CGVHD, a trend towards worse survival was seen in patients with severe disease (3-year probability 57.3% (95% CI 21–82%)) as compared to mild+moderate disease (3-year probability 85.1% (95% CI 68–94)); P=0.1. This analysis, undertaken in a contemporary cohort of related donor recipients, indicates that the consensus guidelines are applicable to this population of CGVHD patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  2. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  3. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14–21.

    Article  CAS  PubMed  Google Scholar 

  4. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  5. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  6. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.

    Article  CAS  PubMed  Google Scholar 

  7. Mielcarek M, Storb R . Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma 2005; 46: 1251–1260.

    Article  CAS  PubMed  Google Scholar 

  8. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546–554.

    CAS  PubMed  Google Scholar 

  9. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74: 1428–1435.

    CAS  PubMed  Google Scholar 

  10. Arora M, Burns LJ, Davies SM, Macmillan ML, Defor TE, Miller WJ et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003; 9: 38–45.

    Article  PubMed  Google Scholar 

  11. Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219–1226.

    Article  CAS  PubMed  Google Scholar 

  12. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.

    Article  Google Scholar 

  13. Lin DY . Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997; 16: 901–910.

    Article  CAS  PubMed  Google Scholar 

  14. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387–394.

    Article  CAS  PubMed  Google Scholar 

  15. Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007; 13: 1207–1215.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA

    M Arora, S Nagaraj, J Witte, T E DeFor, M MacMillan, L J Burns & D J Weisdorf

  2. Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA

    M Arora, S Nagaraj, J Witte, T E DeFor, M MacMillan, L J Burns & D J Weisdorf

Authors
  1. M Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Nagaraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T E DeFor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M MacMillan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L J Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D J Weisdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Arora.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arora, M., Nagaraj, S., Witte, J. et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 43, 149–153 (2009). https://doi.org/10.1038/bmt.2008.305

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.305

Keywords

This article is cited by

Search

Advanced search

Quick links